IPO - Oncocyte Corp

Form Type: S-1

Filing Date: 2025-03-28

Corporate Action: Ipo

Type: New

Accession Number: 000164117225001331

Filing Summary: Oncocyte Corporation has filed a registration statement on Form S-1 with the Securities and Exchange Commission for an initial public offering of up to 10,606,632 shares of its common stock. The shares include 7,536,706 PIPE Shares issued in a private placement and 3,069,926 shares underlying pre-funded warrants. The company aims to democratize access to molecular diagnostic testing, improving patient outcomes through innovative diagnostics. Its focus lies on organ transplant diagnostics that identify early evidence of graft organ damage, as well as oncology tests predicting patient responses to therapies. The company emphasizes a decentralized approach, enabling hospitals and labs worldwide to implement its tests. The proposed sale to the public is set to commence as soon as practicable after the registration statement is declared effective. Oncocyte's shares are currently listed on The Nasdaq Capital Market under the symbol 'OCX,' with the last reported sale price of common stock at $3.22 on March 27, 2025.

Document Link: View Document